SCHEMBL5165953

SCHEMBL5165953

CN(C)C1(c2ccccc2)CCC(NCc2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 19/20 1.00
OPRM1 P35372 17/20 1.00
OPRK1 P41145 2/20 0.53
GRIN2B Q13224 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5166842 0.98 OPRL1 (1.00) OPRL1OPRM1OPRK1GRIN2B
SCHEMBL22089845 0.90 OPRL1 (0.82) OPRL1OPRM1OPRK1
SCHEMBL22101923 0.87 OPRL1 (0.76) OPRL1OPRM1
SCHEMBL22090063 0.87 OPRL1 (0.76) OPRL1OPRM1
SCHEMBL5164651 0.82 OPRL1 (0.72) OPRL1OPRM1OPRK1
SCHEMBL5166695 0.81 OPRM1 (0.67) OPRL1OPRM1
Hydrochloric Acid SCHEMBL5168109 0.81 OPRL1 (0.75) OPRL1OPRM1OPRK1
Hydrochloric Acid SCHEMBL5165668 0.80 OPRM1 (0.68) OPRL1OPRM1
SCHEMBL28658211 0.79 OPRL1 (0.66) OPRL1OPRM1OPRK1
SCHEMBL23699058 0.79 OPRL1 (0.65) OPRL1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392641-B1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-04-11 EP claimed
EP-1392641-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2004-03-03 EP claimed
WO-2002090317-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2002-11-14 WO claimed
US-7276518-B2 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-10-02 US disclosed
EP-1392641-B1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-04-11 EP disclosed
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity GRUENENTHAL GMBH (DE) 2004-11-18 US disclosed
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2004-08-19 US disclosed
EP-1392641-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2004-03-03 EP disclosed
EP-1385493-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2004-02-04 EP disclosed
EP-1385825-A1 SUBSTITUTED 2-PYRIDINE-CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2004-02-04 EP disclosed
WO-2002090317-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2002-11-14 WO disclosed
WO-2002089783-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2002-11-14 WO disclosed
WO-2002090330-A1 SUBSTITUTED 2-PYRIDINE-CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds DPYD, DDC, QDPR OPRL1 1102/4885OPRM1 459/4885OPRK1 274/4885
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity ARG1, CD2, PDCD1 OPRL1 41/4885OPRM1 250/4885OPRK1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.